Beth Good, APRN
Psychiatric/Mental Health, Adult · Cambridge, MNNPI 1568594497
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,550 of the $28,747 with a category attached, or 78.4%. AbbVie accounts for 90.1% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $14,488 and has fallen 99.5% since, to $78 in 2025.
Across 128 payments — averaging $224.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- Neuronetics, Inc.$2K
- Tempus AI, Inc$108
- Neurocrine Biosciences, Inc.$83
- Supernus Pharmaceuticals, Inc.$76
- Teva Pharmaceuticals USA, Inc.$54
- plus $312 from 13 others
What the payments were for
- Speaking & faculty fees$22,55078%
- Travel & lodging$3,53212%
- Food & beverage$2,6359%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $25,909 |
| Neuronetics, Inc. | 12 | $2,205 |
| Tempus AI, Inc | 4 | $108 |
| Neurocrine Biosciences, Inc. | 6 | $83 |
| Supernus Pharmaceuticals, Inc. | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Alkermes, Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Lundbeck LLC | 2 | $27 |
| Indivior Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Corium, LLC | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$24,884
- NEUROSTAR TMS THERAPY SYSTEM$1,971
How this compares
Too few psychiatric/mental health, adult providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 38 | $257,448 |
| VraylarCariprazine Hcl | 144 | $197,694 |
| IngrezzaValbenazine Tosylate | 15 | $119,536 |
| CaplytaLumateperone Tosylate | 36 | $74,484 |
| RexultiBrexpiprazole | 34 | $48,607 |
| LybalviOlanzapine/Samidorphan Malate | 25 | $46,271 |
| Lurasidone Hcl | 171 | $29,756 |
| Risperdal ConstaRisperidone Microspheres | 22 | $29,056 |
| Risperidone ErRisperidone Microspheres | 12 | $19,262 |
| TrintellixVortioxetine Hydrobromide | 34 | $17,305 |
| Divalproex Sodium ErDivalproex Sodium | 238 | $15,032 |
| Paliperidone ErPaliperidone | 67 | $12,996 |
| Olanzapine | 286 | $7,496 |
| FetzimaLevomilnacipran Hcl | 11 | $7,330 |
| Quetiapine Fumarate | 222 | $6,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $54 | $257,44838 claims |
| AbbVieVraylar, Fetzima | $25,909 | $205,024155 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $83 | $119,53615 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $14 | $74,48436 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $14 | $48,60734 claims |
| Alkermes, Inc.Lybalvi | $45 | $46,27125 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $40 | $17,30534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Minnesotaon file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Cambridge
- Samantha HugueletBaxter$1K
- Christine DreselNew Brighton$339
- Joan GibsonEden Prairie$306
- Vicki Dean-GramlichMinneapolis$230
- Kimberly WolfMinneapolis$208
- Jennifer WolfeMinneapolis$94
- Merrie KaasMinneapolis$60
- Julie HeckathorneRichfield$53
- Karen FinckMinneapolis$45
- Judith TiedeMinneapolis$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.